arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

download Export Data

KESTRA MEDICAL TECHNOLOGIES, LTD.

KMTS

$26.11 ▲ +1.38 (+5.58%) at close

3 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4B

Dividend Yield —

Revenue Growth 59.0% ↘

Op. Margin -141.6% ↗

ROIC -316.6% ↘

FCF / Share $-2.15 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 22, 2026.

3-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$95.13M

↑ +59.0% —

Net Income Profit after all expenses

$-131.61M

↓ -15.6% —

Operating Margin Operating profit as % of sales

-141.6%

↑ +20.4% 0th

FCF / Share Free cash flow per share

$-2.15

↑ +47.4% —

Long-Term Debt Long-term obligations

$42.65M

↑ +3.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Financial Health →

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗
Revenue Growth YoY (%)	59.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+638%)	115.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1338%)	—
EPS Growth YoY (%)	52.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-1.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	-15.6% Weak Weak Year-over-year change in net income	-20.9% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	47.4% Excellent Excellent Year-over-year change in free cash flow	3.7% Caution Caution Year-over-year change in free cash flow	—

💰 Are margins durable? 5 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗
Operating Margin (%) (%)	-141.6% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1044%)	-177.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1286%)	-305.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2139%)
Effective Tax Rate (%) (%)	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
Profit Margin (%) (%)	-138.4% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1253%)	-190.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1686%)	-338.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2920%)
FCF Margin (%) (%)	-122.6% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-168.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-303.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%
FCF / Net Income (x)	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 2 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗
Return on Invested Capital (%)	-316.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-259.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-200.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-37.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-36.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-185.1% Weak Weak Operating profit relative to total assets Optimal: > 10%

⚖️ Is the balance sheet risky? 3 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗
Interest Coverage (x)	-23.87x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-21.93x Weak Weak Operating income divided by interest expense Optimal: > 5x	-23.43x Weak Weak Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$-57.06M	$-196.50M	$34.29M
Debt / EBITDA (x)	-0.34x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.42x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.58x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x

📊 What does each share earn? 4 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗
Revenue per Share (USD)	$1.76	$2.43	$1.40
Basic EPS, GAAP (USD)	$-2.43	$-5.13	$-5.07
Free Cash Flow per Share (USD)	$-2.15	$-4.09	$-4.25
Basic Weighted Avg Shares (shares)	54.18M	24.58M	19.89M

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗
Working Capital (USD)	$171.99M	$217.35M	$-18.06M
LT Debt (USD)	$42.65M	$41.10M	$42.54M

📋 What is driving earnings? 4 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗
Sales/Revenue/Turnover (USD)	$95.13M	$59.81M	$27.81M
Depreciation Expense (USD)	$8.71M	$7.97M	$11.56M
Net Income, GAAP (USD)	$-131.61M	$-113.81M	$-94.12M
Operating Cash Flow (USD)	$-81.70M	$-77.61M	$-72.23M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 3 years · 10 quarters

KESTRA MEDICAL TECHNOLOGIES, LTD.

Analytical Summary

3-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare KMTS with peers